Swedish Orphan Biovitrum AB (publ)

SOBI · Nasdaq Stockholm

Public Market Listing

SOBINasdaq Stockholm

Nasdaq Stockholm primary exchange listing

Live quotes, historical charts, and market capitalization for Swedish Orphan Biovitrum AB (publ) are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(6 total)
6Total Assets
3Approved
1Phase 3 / Filed
2Phase 1–2 / Early
8Diseases
Quick filter:
Showing 6 of 6 assets
Target & Modality
Approved
Interleukin-1 Receptor AntagonistProtein / enzyme therapeutic
Rheumatoid Arthritis
Olezarsen(Tryngolza)
Approved
APOC3RNA / oligonucleotide
Familial Chylomicronemia SyndromeSevere HypertriglyceridemiaCardiovascular Disease / Dyslipidemia
Hypertriglyceridemia
Pegcetacoplan(Empaveli)
Approved
Complement C3Peptide
Complement-Mediated Renal DiseaseParoxysmal Nocturnal Hemoglobinuria
Inotersen(Tegsedi)
US approval withdrawn
Transthyretin (TTR)RNA / oligonucleotide
Transthyretin-Mediated Amyloidosis
Transthyretin Amyloidosis with Polyneuropathy
Volanesorsen(Waylivra)No recent activity
Phase 3
APOC3 mRNARNA / oligonucleotide
Familial Chylomicronemia SyndromeSevere Hypertriglyceridemia
Phase 2
KIR3DL2Monoclonal antibody
Cutaneous T-Cell Lymphoma

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
March 2027 (1)
Olezarsen · TryngolzaPhase 3Severe Hypertriglyceridemia
Est. primary completion 2027-03 · NCT05681351 · CT.gov ↗
What to watch
June 2027 (1)
Olezarsen · TryngolzaPhase 3Familial Chylomicronemia Syndrome
Est. primary completion 2027-06 · NCT05185843 · CT.gov ↗
What to watch
July 2027 (1)
Pegcetacoplan · EmpaveliPhase 3C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G) …
Est. primary completion 2027-07 · NCT05809531 · CT.gov ↗
What to watch
2028 (2)
February 2028 (1)
Olezarsen · TryngolzaPhase 3Familial Chylomicronemia Syndrome
Est. primary completion 2028-02 · NCT05130450 · CT.gov ↗
What to watch
December 2028 (1)
Pegcetacoplan · EmpaveliPhase 2Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Hemoglobinuria
Est. primary completion 2028-12 · NCT04901936 · CT.gov ↗
What to watch
2030 (1)
August 2030 (1)
Olezarsen · TryngolzaPhase 3Familial Chylomicronemia Syndrome
Est. primary completion 2030-08 · NCT07727538 · CT.gov ↗
What to watch
2031 (1)
January 2031 (1)
Pegcetacoplan · EmpaveliPhase 3C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) …
Est. primary completion 2031-01-17 · NCT07898774 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

17 November 2026ApprovalOlezarsenEuropean Commission approves Tryngolza in severe hypertriglyceridaemia
EU, European Commission · Source ↗
19 May 2025Topline resultOlezarsenPhase 3 Essence (NCT05610280) of olezarsen met its primary endpoint
Ionis Pharmaceuticals · Source ↗
14 February 2025WithdrawalInotersenFDA withdrew approval of Tegsedi (NDA 211172) at the holder's request
US, FDA · FDA · Source ↗

Financial reports

No financial reports recorded.